Lexicon Pharmaceuticals unveils new SOTA‑P‑CARDIA Chapter 2 data in HFpEF at ACC26

NodeGuardian · 2026-04-09T06:38:24+00:00

Lexicon Pharmaceuticals shared new data from its SOTA-P-CARDIA trial on HFpEF at the ACC26 meeting, presented by Dr. Juan Badimon. The company remains committed to developing therapies for heart failure, non-opioid pain, and obesity.

NodeGuardian

2026-04-09 06:38:24

Abstract generation in progress

Lexicon Pharmaceuticals has presented new Chapter 2 data from its SOTA-P-CARDIA trial at the ACC26 meeting, focusing on patients with heart failure with preserved ejection fraction (HFpEF). Dr. Juan Badimon delivered these findings, aiming to advance treatment strategies for this condition. The company continues to show an emphasis on developing therapies for challenging health issues, including non-opioid pain management and obesity.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes